Cargando…
EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747425/ http://dx.doi.org/10.1016/j.jval.2022.09.434 |
| _version_ | 1784849595088502784 |
|---|---|
| author | Paret, K Beyhaghi, H Herring, W Rousculp, M Toback, S Mauskopf, J |
| author_facet | Paret, K Beyhaghi, H Herring, W Rousculp, M Toback, S Mauskopf, J |
| author_sort | Paret, K |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9747425 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97474252022-12-14 EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States Paret, K Beyhaghi, H Herring, W Rousculp, M Toback, S Mauskopf, J Value Health Article Published by Elsevier Inc. 2022-12 2022-12-14 /pmc/articles/PMC9747425/ http://dx.doi.org/10.1016/j.jval.2022.09.434 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Paret, K Beyhaghi, H Herring, W Rousculp, M Toback, S Mauskopf, J EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States |
| title | EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States |
| title_full | EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States |
| title_fullStr | EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States |
| title_full_unstemmed | EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States |
| title_short | EE184 Assessing the Cost-Effectiveness of the Novavax COVID-19 Vaccine as a Potential Booster Vaccine Option for Adults in the United States |
| title_sort | ee184 assessing the cost-effectiveness of the novavax covid-19 vaccine as a potential booster vaccine option for adults in the united states |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747425/ http://dx.doi.org/10.1016/j.jval.2022.09.434 |
| work_keys_str_mv | AT paretk ee184assessingthecosteffectivenessofthenovavaxcovid19vaccineasapotentialboostervaccineoptionforadultsintheunitedstates AT beyhaghih ee184assessingthecosteffectivenessofthenovavaxcovid19vaccineasapotentialboostervaccineoptionforadultsintheunitedstates AT herringw ee184assessingthecosteffectivenessofthenovavaxcovid19vaccineasapotentialboostervaccineoptionforadultsintheunitedstates AT rousculpm ee184assessingthecosteffectivenessofthenovavaxcovid19vaccineasapotentialboostervaccineoptionforadultsintheunitedstates AT tobacks ee184assessingthecosteffectivenessofthenovavaxcovid19vaccineasapotentialboostervaccineoptionforadultsintheunitedstates AT mauskopfj ee184assessingthecosteffectivenessofthenovavaxcovid19vaccineasapotentialboostervaccineoptionforadultsintheunitedstates |